▷ BioVaxys continues to expand intellectual property portfolio in global markets


29.10.2021 – 07:27

BioVaxys Technology Corp.

Vancouver, British Columbia (ots/PRNewswire)

– Registrations for international patent and trademark protection from CoviDTH

BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) (“BioVaxys” or “Company”) announced today that it has patented CoviDTH, its T-cell diagnostic agent for detecting an immune response to SARS CoV-2, by filing an international patent application under the Patent Cooperation Treaty (“PCT”), has expanded to include broad geographic market coverage outside the United States. Although the CoviDTH diagnostic results are intended to be interpreted visually by a trained technician or healthcare provider, other claims include data acquisition and analysis through methods such as optical, infrared, and ultrasound image processing.

The Patent Cooperation Treaty (“PCT”), a patent treaty with more than 150 member countries, enables an invention to be patented simultaneously in a large number of countries by filing a single “international” patent application, instead of filing multiple separate national or regional patent applications.

BioVaxys also recently filed international filings for the CoviDTH trademark in select markets such as Canada, Mexico, the European Union and the United Kingdom. Six months ago, the company applied to the United States Patent and Trademark Office (“USPTO”) to register its “CoviDTH” trademark in the United States. Trademark applications in certain jurisdictions may be treated as if they were filed on the filing date of the U.S. application, provided that applications are filed within six months of the U.S. filing date. BioVaxys can apply for the trademark registration of CoviDTH in other countries at a later date, but without the benefit of the earlier US filing date.

James Passin, CEO of BioVaxys, said: “Given the urgent need to commercialize a low-cost diagnostic of T-cell immunity to Covid-19 in the context of the global pandemic, we believe it is critical to protect intellectual property in key international markets as we continue to work towards filing an IND in the United States. “

BioVaxys makes no claims, express or implied, that it is able to treat the SAR-CoV-2 virus at this point in time.

About BioVaxys Technology Corp.

The Vancouver-based BioVaxys Technology Corp. (www.biovaxys.com) is a British Columbia registered clinical phase biotechnology company developing viral and oncological vaccine platforms and immunodiagnostics. The company is developing a SARS-CoV-2 vaccine based on its haptenized viral protein technology and is preparing a clinical trial of its haptenized autologous cell vaccine in combination with anti-PD1 and anti-PDL-1 checkpoint inhibitors, initially for ovarian cancer is to be developed in stage III / stage IV. CoviDTH®, a diagnostic tool for assessing the presence or absence of a T-cell immune response to SARS-CoV-2, the virus that causes Covid-19, is also under development. BioVaxys has several issued U.S. patents and pending patent applications related to its cancer vaccine and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies. BioVaxys’ common stock is listed on the CSE under the symbol “BIOV” and is listed on the Frankfurt Stock Exchange (FRA: 5LB) and in the United States (OTCQB: BVAXF).

ON BEHALF OF THE BOARD OF DIRECTORS

Signed “James Passin”

James Passin, CEO

+1 646 452 7054

Cautious Statements Regarding Forward-Looking Information

This press release contains certain “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of applicable Canadian and US securities laws including the United States Private Securities Litigation Reform Act of 1995. Any statements contained herein that may not differ Relating to historical facts, in particular statements about the future operational or financial performance of the company, are forward-looking statements. Forward-looking statements are often, but not always, identified by words such as “expected,” “anticipated,” “believes,” “intends,” “estimates,” “potentially,” “possible” and similar expressions, or by statements that events will occur , Conditions or results “will”, “may”, “could” or “should”. Forward-looking statements in this press release relate to, among other things, the completion of the mouse model study, regulatory approval for a Phase I human vaccine candidate BVX-0320, and the general development of BioVaxys’ vaccines, including a haptenized SARS-Cov -2 protein vaccine. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those expressed or implied in such forward-looking statements.

These forward-looking statements reflect the beliefs, opinions and projections at the time the statements were made and are based on a number of assumptions and estimates, most notably the belief that BioVaxys will be successful in developing and testing vaccines will be. While Company believes these assumptions and estimates are reasonable, they are inherently subject to significant business, economic, competitive, political and social uncertainties and uncertainties, including the risk that BioVaxys’ vaccines will prove ineffective and / or not Obtain the necessary regulatory approvals. In relation to BioVaxys’ business, there are a number of risks that could affect the development of its biotechnological products including, but not limited to, the need for additional capital to fund clinical trials, its lack of operational history, and uncertainty as to whether its products going through the long, complex, and expensive clinical trial and regulatory approval process for new drugs required for market approval; the uncertainty that his autologous cell vaccine immunotherapy can be engineered to produce safe and effective products; and If so, whether their vaccine products will be commercially acceptable and profitable, the expenses, delays, and uncertainties and complications that biopharmaceutical companies typically face in the development phase, financial and development-related obligations under licensing agreements agreements to protect their rights to their products and technologies, the acquisition and protection of new intellectual property rights and the avoidance of infringement against third parties, as well as their dependence on third-party manufacturing.

The company assumes no obligation to update any forward-looking statements of beliefs, opinions, projections or other factors if they change unless required by law.

Medienkontakte BioVaxys Technology Corp.
Gina Cestari, Senior VP
 6 Degrees Public Relations
+1 917 797 7904

Logo: https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg

Original content by: BioVaxys Technology Corp., transmitted by news aktuell


www.presseportal.de

Leave a Reply

Your email address will not be published. Required fields are marked *